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Prions are a unique group of proteinaceous pathogens which cause neurodegenerative disease and can be transmitted by a variety
of exposure routes. After peripheral exposure, the accumulation and replication of prions within secondary lymphoid organs are
obligatory for their efficient spread from the periphery to the brain where they ultimately cause neurodegeneration and death.
Mononuclear phagocytes (MNP) are a heterogeneous population of dendritic cells (DC) andmacrophages.These cells are abundant
throughout the body and display a diverse range of roles based on their anatomical locations. For example, some MNP are
strategically situated to provide a first line of defence against pathogens by phagocytosing and destroying them. Conventional DC
are potent antigen presenting cells andmigrate via the lymphatics to the draining lymphoid tissue where they present the antigens to
lymphocytes.The diverse roles of MNP are also reflected in various ways in which they interact with prions and in doing so impact
on disease pathogenesis. Indeed, some studies suggest that prions exploit conventional DC to infect the host. Here we review our
current understanding of the influence of MNP in the pathogenesis of the acquired prion diseases with particular emphasis on the
role of conventional DC.
1. Introduction
Prion diseases, or transmissible spongiform encephalop-
athies, are subacute neurodegenerative diseases affecting
humans and certain domestic and free-ranging animal spe-
cies. These diseases are characterized by the presence of
aggregations of PrPSc, abnormally folded isoforms of the cel-
lular prion protein (PrPC), in affected tissues. Although the
precise nature of the infectious prion is still the subject of
intense debate, prion infectivity copurifies with PrPSc which
is considered to constitute the major component of the infec-
tious agent [1, 2]. The accumulation of PrPSc in the central
nervous system (CNS) of prion-infected hosts is accompa-
nied by neuronal loss, spongiosis, and reactive glial responses
(Figure 1). Someprion diseases appear to have idiopathic aeti-
ology. These may arise spontaneously within the CNS (such
as sporadic Creutzfeldt-Jakob disease (CJD)) or are asso-
ciated with polymorphisms within the PRNP gene (which
encodes PrPC) which some consider predisposes the prion
protein to abnormally fold into the disease-specific isoform
(such as Gerstmann-Straussler-Scheinker syndrome). Many
other prion diseases, including natural sheep scrapie, bovine
spongiform encephalopathy, and chronic wasting disease
in cervids and kuru and variant Creutzfeldt-Jakob disease
(vCJD) in humans, are acquired following exposure to prions,
for example, by oral consumption of prion-contaminated
food. For the efficient transmission of prions to the CNS
after peripheral exposure (a process termed neuroinvasion),
the replication of prions within secondary lymphoid tis-
sues is crucial [3]. Within lymphoid tissues, prions repli-
cate upon stromal-derived follicular dendritic cells (FDC)
located within the B cell follicles [4–6] (Figure 2). Following
their replication and amplification upon FDC, the prions
subsequently spread along neurones of the sympathetic
and parasympathetic nervous systems, accessing the CNS
wherein they ultimately cause neurodegeneration resulting in
the death of the host [7–10].
Mononuclear phagocytes (MNP) arise from haematopoi-
etic precursor cells within the bone marrow and are a
heterogeneous population of monocytes, macrophages, and
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Figure 1: Neuropathological characteristics of prion disease within the brains of clinically affected mice. (a) Prion diseases are characterized
by the presence of aggregations of abnormally folded, disease-specific prion protein (PrP) in affected tissues (brown). In the brain, as shown
here, these accumulations are accompanied by extensive neuronal loss, spongiform change (indicated by vacuolation in panel “(b)”), reactive
microglia (Iba1+ cells, panel “(c),” brown), and reactive astrocytes expressing high levels of glial fibrillary acidic protein (GFAP, panel “(d),”
brown). Sections are counterstained with haematoxylin (blue).
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Figure 2: Stromal-derived follicular dendritic cells are important sites of prion accumulation and replication in the B cell follicles of secondary
lymphoid tissues. Detection of high levels of abnormally folded, disease-specific prion protein (PrP, brown) in Peyer’s patches, mesenteric
lymph nodes (MLN), and spleen of a mouse infected with ME7 scrapie prions. Sections are counterstained with haematoxylin (blue).
dendritic cells [11–13]. These cells are abundant throughout
the body and possess a diverse range of functions based
on the anatomic locations they occupy. For example, some
MNP are strategically situated at exposure sites such as the
skin or intestinal lamina propria to provide a first line of
defence against pathogens by phagocytosing and destroying
them in their phagolysosomal compartments. Others, such
as conventional dendritic cells (DC), are potent antigen
presenting cells and provide an important link between the
innate and adaptive immune systems.TheseMNP are located
to efficiently sample host tissues and fluids for pathogens
and their antigens (Figure 3). The immature conventional
DC at these sites are highly phagocytic. Following the
uptake of pathogens or antigens, these cells typically undergo
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Figure 3:Mononuclear phagocytes (MNP) are a heterogeneous population ofmonocytes, macrophages, and dendritic cells and are abundant
throughout the body. MNP are strategically situated at exposure sites such as in the epidermis or dermis of the skin (panels “(a)” and
“(b),” resp.) and in the intestinal lamina propria where they provide a first line of defence against pathogens. (a and b) Whole-mount
immunohistochemical detection of langerin+ Langerhans cells in the epidermis (green, panels “(a)”) and langerin+ conventional DC in the
dermis (green, panels “(b)”). The boxed region in the upper panels is shown at higher magnification in the adjacent lower panels. (c) CD11c+
MNP (red) are abundant in Peyer’s patches and the intestinal lamina propria. SED, subepithelial dome region on Peyer’s patch; V, villus;
broken line indicates the boundary of the epithelium overlying Peyer’s patch.
maturation and migrate via the lymphatics to the draining
(regional) lymphoid tissue, such as the mesenteric lymph
nodes (MLN) associated with the intestine [14], where they
present the antigens to lymphocytes to initiate an antigen-
specific (adaptive) immune response or induce tolerance [15].
Other MNP populations appear to play an important role
within lymphoid tissues in the transfer of intact antigens to
B cells [16, 17]. In this review, it is important to remember
that the migratory, bone marrow-derived conventional DC
[15] are entirely distinct from the stromal derived FDC [18,
19] which have been shown to be the critical sites of prion
replication in lymphoid tissues [6]. The FDC, in contrast, are
localized within B cell follicles of lymphoid tissues, derive
from ubiquitous perivascular precursor cells [19], are tissue
fixed and nonphagocytic. In contrast to conventional DC,
FDC are long-lived cells which can retain native antigens on
their surfaces for long periods.
Viable commensal bacteria can be recovered from DC
migrating from the intestine [20] and some pathogenic
microorganisms may exploit DC as an efficient way to infect
host tissues [21]. In the transient absence of CD11c+ DC at the
time of peripheral exposure, the early accumulation of prions
in the draining lymphoid tissue was blocked and disease
susceptibility reduced [22–24]. These data imply that prions
may also exploit conventional DC to infect the host. Thus, in
this review we discuss our current understanding of the role
of MNP in the pathogenesis of the acquired prion diseases
with particular emphasis on conventional DC.
2. Conventional DC:
A Multifunctional Cellular Component of
the Innate Immune System
MNP such as conventional DC exhibit a diverse array of
functions in the mammalian innate immune system. This
is reflected in the various ways in which they may interact
with prions, and, by doing so, impact on prion disease patho-
genesis (Figure 4). Following their uptake by conventional
DC, the prions may (i) activate innate immune responses
and be sequestered and partially degraded within the cell’s
phagolysosomal compartments; (ii) undergo amplification
(replication) since these cells express the substrate PrPC; (iii)
activate acquired immune responses and induce a specific
4 Journal of Immunology Research
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Figure 4: The influence of DC on prion disease pathogenesis. (1) Conventional DC are strategically placed throughout the mammalian host
and are amongst the first cell populations to interact with prions. Following their uptake of prions DC have been proposed to exert a diverse
range of contrasting effects on prion disease pathogenesis which may have a significant outcome on the spread of infection to the CNS. (2)
Some studies have suggested that DCmay help to protect the host against infection by attempting to sequester and destroy the prions [25–29].
(3) Others suggest that prionsmay exploit themigratory characteristics of DC to facilitate their efficient propagation from the site of exposure
to the lymphoid tissues [22–24, 34, 39]. (4) DCmay also play an important role in the subsequent transfer of prions to the CNS by bridging the
gap between the immune and peripheral nervous systems [36, 61, 91–93]. (5) The adoptive transfer of PrP peptide-loaded DC into mice can
overcome host tolerance towards PrP and prolong survival time after prion infection. This implies that DC could be manipulated to provide
immunotherapeutic protection against prion diseases [54, 106, 107]. (6) The physiological function of cellular PrPC is uncertain but in DC
may play a role in the immune synapse or in the regulation of cell migration [51, 52].
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immune response to prions as conventional DC are potent
antigen-presenting cells; (iv) be conveyed from the site of
exposure to sites of prion replicationwithin the draining lym-
phoid tissue. The sections below describe the many studies
which have attempted to address the potential contribution
of these roles to prion disease pathogenesis.
3. In Vitro Cultivated DC Can
Acquire and Destroy Prions
“Immature” conventional DC are highly phagocytic cells and
have the potential to sequester and destroy prions in a similar
manner to that in which they process peptide antigens for
presentation to T cells in association withMHC class II. Data
from several independent studies support this hypothesis and
have shown that in vitro cultivated DC-like cells can readily
acquire and degrade prions [25–28]. Within these cells, the
prion-specific PrPSc appears to be preferentially degraded by
cysteine proteases [29]. These data are congruent with data
from similar studies using macrophages which show they
can also acquire and degrade prions after extended in vitro
exposure [30, 31]. Whether these data accurately reflect the
handling and processing of prions by conventional DC in
vivo is uncertain since these cells can retain high levels of
infectious prions in infected rodents [32–36]. Furthermore,
when macrophages are depleted in vivo in prion-infected
hosts, higher concentrations of prions are recovered from
their lymphoid tissues [37, 38]. In contrast, depletion of
CD11c+ cells impedes the early accumulation of prions in the
draining lymphoid tissue [22–24, 39] (see below).
4. DC Are Not Important Sites
of Prion Replication
Although conventional DC are typically considered to inter-
nalize antigens which they then process into short peptides
and present themon their surfaces to T cells, someMNPpop-
ulations including certain conventional DC subsets appear
to be equipped with both degradative and nondegradative
antigen handling pathways [40, 41]. These distinct pathways
may enable conventional DC to present processed peptide
antigens to T cells or native antigens to B cells. During prion
infection DC can sequester high levels of prions [32–36],
but these cells are highly unlikely to be acting as important
early sites of prion replication or amplification. Expression
of the cellular prion protein, PrPC, is obligatory for prion
replication, and MNP including conventional DC in mice,
humans, and cattle express PrPC on their surfaces [42–44].
However, several studies have shown that prion replication
within the secondary lymphoid tissues and disease pathogen-
esis are not influenced by the absence of PrPC expression in
haematopoietic cells [6, 45–48]. Thus, the role of DC during
prion pathogenesis is more complex than simply acting as
sites of prion replication.
5. The Enigmatic Function of PrPC in
the Immune System
The cellular prion protein, PrPC, is 30–35 kDa glycoprotein
linked to the cell surface via a glycosylphosphatidylinositol
anchor. The precise function of PrPC in mammalian cells
remains elusive, but the expression of PrPC by many immune
cell populations, including conventional DC, implies a role
in immune function [42–44]. However, mice that lack PrPC
expression in the haematopoietic compartment display no
obvious immune deficit and are able to maintain antigen-
specific antibody responses and affinity maturation [49].
Some studies have suggested that PrPC may regulate phago-
cytosis. Upon further scrutiny, a separate study revealed that
the reduced ability of MNP to phagocytose apoptotic cells in
Prnp−/− mice was due to effects on a linked locus encoding
the signal regulatory protein 𝛼 (Sirpa) gene rather than
the absence of PrPC expression [50]. Microscopical analyses
show PrPC accumulates at contact sites between T cells
and antigen-loaded conventional DC implying a role in the
immune synapse between these cell populations. Consistent
with this, the absence of PrPC in antigen-presenting cells
impacted on their ability to stimulate T cells [51].
A separate study has proposed that PrPC may regulate
human monocyte migration by modulating cell adhesion
dynamics [52]. The authors propose that PrPC regulates 𝛽1-
integrin-mediated adhesion by modulating the remodelling
of the actin cytoskeleton through the RhoA-cofilin pathway.
6. Induction of Specific Immunity
against Prions
Although conventional DC are potent antigen-presenting
cells and play an important role in the induction of antigen-
specific immune responses, these cells are unlikely to play a
role in the induction of specific immunity against prions.The
prion protein is tolerated by the host immune system due
to the widespread expression of PrPC throughout the body.
This prevents the induction of specific cell-mediated and
antibody-mediated immune responses to PrPSc, the major
component of infectious prions [53]. Despite this, a cell-based
immunotherapy approach may be possible against prions as
experiments have shown that the adoptive transfer of PrP
peptide-loaded conventional DC into mice can overcome
host tolerance towards PrP and prolong survival time after
peripheral prion exposure [54].
7. DC and the Propagation of Prions to
Draining Lymphoid Tissues
Some DC populations have been shown to have the ability
to capture and retain unprocessed antigens in their native
states and transfer them intactly to na¨ıve B cells to initiate
a specific antibody response [17]. Viable commensal bacteria
can also be recovered from conventional DC migrating from
the intestine [20]. The demonstration that some pathogenic
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microorganisms appear to exploit migratory DC to enable
their delivery to lymphoid tissues [21, 55–57] raised the
hypothesis that DCmay play a similar role in the initial deliv-
ery of prions from the site of infection (such as the gut lumen)
to the draining lymphoid tissues (such as the gut-associated
lymphoid tissues after oral exposure). This hypothesis was
further supported by the observation that some migrating
intestinal DC in the afferent mesenteric lymph had acquired
PrPSc following its injection into the gut lumen [34]. Sub-
sequent studies have since shown that, in the absence of
migratory DC at the time of peripheral exposure, the early
accumulation of prions in the draining lymphoid tissue
and the subsequent spread of disease to the CNS are both
impeded [22–24, 39]. However, not all DC subsets appear to
share this property. For example, whereas the depletion of
CD11c+ cells (using CD11c-DTR-eGFP-tg mice) dramatically
impedes oral prion pathogenesis [22], specific depletion of
CD8+CD11c+ cells (using CD11c-N17Rac1-tg mice) does not
[24]. Similarly, prion pathogenesis following infection via
skin lesions was impaired in the specific absence of CD11c+
langerin− dermal DC but was not affected in the absence of
epidermal Langerhans cells or langerin+ dermal DC [39].
Chemokines help to attract lymphocytes and DC to
lymphoid tissues and control their positioning within them.
For example, the chemokines CCL19 and CCL21 are consti-
tutively expressed by stromal cells within the T cell zones and
mediate the homing of chemokine receptor CCR7-expressing
na¨ıve T cells and mature DC towards them [58]. The posi-
tioning of DC within the interfollicular T cell regions of
Peyer’s patches and their steady-state migration from Peyer’s
patches to the MLN are likewise dependent upon CCR7-
CCL19/CCL21-signalling [59]. However, the CCL19/CCL21-
mediated attraction of DC is unlikely to influence prion
neuroinvasion from Peyer’s patches since oral prion patho-
genesis is unaffected in pltmice which lack CCL19 andCCL21
[33]. This observation is consistent with data from other
studies showing that Peyer’s patches in the small intestine,
not the MLN which collect the lymph and cells draining
the intestine [14], are the critical sites of prion accumulation
and neuroinvasion after oral prion exposure [3, 60]. Prion
pathogenesis is likewise unaffected in the specific absence of
T cells [61].
The demonstration that the accumulation of prions upon
FDC in the draining lymphoid tissues was prevented in
the absence of DC at the time of exposure [22–24, 39]
implied that prions exploit these cells to access the draining
lymphoid tissue, perhaps by using them as “Trojan horses.”
The detection of PrPSc-containing DC within the villous
lacteals and submucosal lymphatics in the intestines of sheep
soon after exposure to prions by oral infection or by injection
into ligated gut loops implies a similar role [62–64]. Distinct
DC subsets have been described that can transport native
antigen to B cells in vivo [17, 65, 66].The chemokine CXCL13
is highly expressed by FDC and follicular stromal cells in
the B cell follicles of lymphoid tissues and modulates the
homing of CXCR5-expressing B cells into them [67, 68].
The migration of certain populations of splenic DC and
dermal DC into B cells follicles is also mediated by CXCL13-
CXCR5 signalling [69, 70]. During virus infection, DCwithin
the medullary sinus have been shown to capture lymph-
borne influenza virus particles and subsequently migrate
to the FDC-containing B cell follicles [71]. Further studies
are clearly necessary to determine whether, after acquiring
prions, DC similarly migrate similarly towards B cell follicles
and in doing so infect FDC.
Although several studies suggest that DC may play an
important role in the initial delivery of prions to and within
the draining lymphoid tissues, the possibility that some of the
prions may enter these tissues in a cell-free manner should
not be excluded [39, 72, 73].
8. How Do DC Acquire Prions?
Whether DC acquire and endocytose prions via a specific
receptor or receptors is uncertain, but the neurotoxic prion
protein fragment PrP
106–126 is a chemoattractant for mon-
ocyte-derived DC [74]. Some MNP subsets express cellular
PrPC highly which may itself act as a receptor for prion-
specific PrPSc [42–44]. However, if DC do acquire some
prions in a PrPC-dependent manner, it does not play a major
role in disease pathogenesis. The propagation of prions from
various peripheral sites of exposure to FDC and their
subsequent neuroinvasion are not influenced by a lack of
PrPC expression by haematopoietic cells [6, 45–48]. These
observations suggest the existence of other receptors on the
surfaces of DC besides PrPC that they may use to acquire
prions.
The FDC within the B cell follicles are considered to
acquire prions in the form of complement-opsonized com-
plexes [75, 76]. Conventional DC may similarly indirectly
acquire prions following their opsonisation by complement
components such as C1q and C3 [72, 77]. The comple-
ment C1q-dependent uptake of prions by conventional DC
appeared to be complement receptor- (CR-) mediated [77].
The identity of the specific receptor which mediates the
uptake of complement-opsonized prions by conventional DC
is uncertain, but many candidate molecules such as CR1
(CD35), CR2 (CD21), CR4 (CD11c/CD18), calreticulin, CD93,
and SIGN-R1 (CD209b) are expressed by specific populations
of these cells and can bind C1q [72, 77]. In other studies, it
is interesting to note that the SIGN-R1-mediated uptake of
influenza virus by DC lining the medullary sinus of lymph
nodes stimulates their subsequent migration towards FDC
[71]. After oral exposure, it is possible that the prions are
acquired from the gut lumen in complex with dietary ferritin
[78]. Finally, since MNP such as conventional DC are highly
phagocytic, they may simply acquire prions nonspecifically
as the cells constitutively sample their microenvironment, for
example, via micropinocytosis.
9. Plasmacytoid DC also Sequester Prions
The plasmacytoid DC are a distinct subset of MNP which
rapidly secrete large amounts of type I interferon (IFN-𝛼/𝛽)
in response to foreign nucleic acids such as during virus infec-
tion [79]. One study has shown that plasmacytoid DC, like
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conventional DC, can also sequester high levels of infectious
prions during infection [36]. The consequences that this may
have on prion disease pathogenesis are uncertain. Plasmacy-
toidDC are unlikely to play a role in the propagation of prions
to the draining lymphoid tissues since these cells do not
migrate in the lymphatics during the steady-state or following
activation [80]. Plasmacytoid DC also express negligible
levels of PrPC, even after activation, so like classical DC they
are unlikely to be important sources of prion replication [81].
Prion disease also does not induce the synthesis of significant
levels of IFN [82–84], and treatment of mice soon after
prion infection with polyriboinosinic-polyribocytidylic acid
(poly(I:C)), which stimulates type I IFN production, does not
alter disease pathogenesis [85, 86]. Splenic plasmacytoid DC
may simply be attempting to sequester and destroy prions
following their amplification by FDC. However, some studies
have suggested that plasmacytoid DC and classical DC [36,
87] may play a role in prion neuroinvasion by facilitating the
subsequent propagation of prions to peripheral nerves (see
below).
10. DC and the Propagation of Prions between
the Immune and Nervous Systems
Following their amplification upon FDC prions subsequently
infect the peripheral nerves within the lymphoid tissue [8,
9, 88]. The prions then spread along the nerves of both
the sympathetic and parasympathetic nervous systems and
subsequently infect the CNS where they cause neurodegen-
eration leading to the death of the host [9, 10]. How prions
spread between FDC and peripheral nerves is not known
as these cells do not make significant physical contacts or
synapses. Within peripheral tissues, there is much crosstalk
between MNP and peripheral nerves. For example, in the
intestine MNP/conventional DC are abundant in the mus-
cular layer where they interact with enteric neurones and
help regulate gastrointestinal motility [89, 90]. Given their
migratory properties, experiments have sought to determine
whether DC might also bridge the gap between FDC and
peripheral nerves during prion disease.
Data from in vitro coculture studies show that prion-
infected DC could potentially transfer prions to primary
neurones ormouse neuroblastomaN2a cells [91–93]. Efficient
prion transfer between these populations required cell-cell
contact [92, 93]. Furthermore, when fixed bone marrow-
derived DC were used, this activity was blocked implying an
active process was required [92]. Data from a detailed in vitro
study have proposed that tunnelling nanotubes (TNT), thin
membrane-bound cylinders of cytoplasm which can connect
neighbouring cells, might represent a novel method through
which the intracellular exchange of prions between these cells
may occur [91]. Within the TNT the PrPSc appears to travel
in endolysosomal vesicles [94]. Whether significant transfer
of prions between cells by TNT occurs in the dynamic
environment of the lymphoid tissues in vivo remains to
be determined. However, the analysis of lymphoid tissues
from HIV patients shows intercellular transfer via a similar
mechanism is possible. Xu and colleagues revealed that HIV-
1-infected macrophages were able to establish long range
intercellular connections (consistent with TNT) with B cells
[95]. These intercellular conduits were exploited by the virus
to deliver a virus encoded immunosuppressive factor to B
cells to enable it to suppress the humoral response.
Prions have also been proposed to be released from
infected cells in the form of small endosomal-derived vesicles
termed exosomes [96]. Therefore, during prion infection DC
may also release significant amounts of infectious prions in
this manner and in doing so enhance their ability to infect
neighbouring cells [36].
An in vivo study has suggested that prion-infected DC
alone are potentially sufficient to transfer infection directly
to the nervous system. Immunodeficient Rag1−/− mice lack
T and B cells and are indirectly deficient in FDC. As a
consequence thesemice are refractory to peripheral infection
with prions [61]. Despite this, live prion-infected DC were
sufficient to transmit disease after intravenous injection into
Rag1−/− mice [32]. Since these mice lack mature FDC and
are unable to replicate prions in their lymphoid tissues, these
data implied that the DC had transferred the prions directly
to the peripheral nervous system. However, an indepen-
dent study using FDC-deficient Tnfr1−/− mice was unable
to demonstrate significant direct infection of the nervous
system by prion-infected DC [35]. The precise reason for
the discrepancy between these two studies is uncertain but
may relate to the much higher density of peripheral nerves
in the spleens of Rag1−/− mice when compared to Tnfr1−/−
mice [35]. Clearly further studies are necessary to determine
the precise contribution of DC and DC-derived tunnelling
nanotubes or exosomes to the transfer of prions between FDC
and peripheral nerves in vivo.
A subset of MNP with apparent conventional DC charac-
teristics has been described in the mouse brain [97]. Within
the brains of variant CJD patients deposits of PrPSc have
been described in vascular-associated DC [98], and another
study has proposed that CD205+ (DEC-205) expressing DC
may also migrate into the murine brain during prion disease
[99]. Under certain circumstances, monocytes may also
traffic to the brain and, in doing so, act as potential vectors
for the delivery of pathogens such as virus or prions or
misfolded aggregates of Alzheimer’s disease-related amyloid
𝛽 protein [100]. The possibility cannot therefore be entirely
exclude that prion-infected conventional DC contribute to
the establishment of prion infection in theCNS. Complement
components C1q and C3 associate with PrPSc in the brains of
prion-infected mice [101], raising the possibility that prions
are acquired by DC in the CNS in a complement-dependent
manner [72, 77].
Thedetection of prion-specific PrPwithin the circumven-
tricular organs of the brain has been reported to be an early
feature in scrapie-affected sheep [102]. Due to the presence
of their fenestrated capillaries, the circumventricular organs
are important sites of molecular exchange between the
blood stream and the CNS. However, during prion disease
monocytic infiltration into the circumventricular organs is
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were then constructed using only those sample-to-sample relationships greater than 𝑟 = 0.9 and clustered with an MCL inflation value of
2.2. Each node represents an individual microarray data set and the edges are coloured on a sliding scale according to the strength of the
correlation (red, 𝑟 = 1.0; blue, 𝑟 = 0.9). Each cluster of samples was assigned a different colour. Each of these analyses shows that at the
transcriptomic level the in vitro bone marrow-derived DC (BMDC) or monocyte-derived DC (MDDC) prepared from mice (panel “(a)”)
and humans (panel “(b)”) are indistinguishable frommacrophages and do not cluster with conventional DC enriched from tissues such as the
spleen, tonsils, or peripheral blood.The tissueDC, BMDC, andMDDCdata sets are highlighted in red font. Reference [11] provides full details
about the sources of all the 304 individual microarray data sets used in “(a).” Reference [105] provides full details about the sources of all the
745 microarray data sets used in “(b).” BMDC, bone marrow-derived dendritic cells; BMDM, bone marrow-derived macrophage; anthrax,
Bacillus anthracis edema toxin; CMP, commonmyeloid progenitors; ES, embryonic stem cell; GMP, granulocyte monocyte progenitors; HSC,
haematopoietic stem cell; IKDC, interferon-producing killer DC; MDDC, monocyte-derived DC; MDM, monocyte-derived macrophage;
MEP,megakaryocyte-erythroid progenitor cell; MkP,megakaryocyte progenitors;MSC,mesenchymal stem cells; NK, natural killer; PreCFU-
E, preerythroid progenitors; PreMegE, premegakaryocyte/erythroid; PB, peripheral blood; Treg, regulatory T cell. Panel “(a)” is reproduced
from [11] with permission from Elsevier. Panel “(b)” is reproduced from [105] under the terms of the Creative Commons Attribution License
2.0.
Journal of Immunology Research 9
not observed arguing against the cell-associated haematoge-
nous spread of prions into the CNS. Studies in mice also
show that CCR2-deficiency and absence of recruitment of
circulating monocytes do not significantly impact on prion
disease pathogenesis within the CNS [103]. The depletion
of sympathetic nerves dramatically impedes the spread of
prions from lymphoid tissues to the CNS [10]. Conversely,
prion pathogenesis after peripheral exposure is exacerbated
by treatments which increase the density of sympathetic
nerves in lymphoid tissues [10] or in mice in which the dis-
tance between FDC and sympathetic nerves is reduced [88].
These findings are consistent with the conclusion that prions
initially infect the CNS via their spread along peripheral
nerves rather than direct haematogenous transfer.
11. Conclusions
11.1.TheManyFaces ofDCduring PrionDisease. Asdescribed
above, DC have been proposed to exert a diverse range of
contrasting effects on prion disease pathogenesis which may
have a significant outcome on the spread of infection to
the CNS. Some studies have suggested that DC may help to
protect the host against infection by attempting to sequester
and destroy the prions. Others suggest that prions may
exploit the migratory characteristics of prions to facilitate
their efficient propagation from the site of exposure to the
lymphoid tissues. DC may also play an important role in the
subsequent transfer of prions to the CNS by bridging the
gap between the immune and peripheral nervous systems
(Figure 4).
11.2. DC or Not DC? While it is evident from data described
above that the actions of certain MNP populations may
significantly influence the outcome of a peripheral prion
infection, it is uncertain whether the cells involved actually
are DC. Indeed there is much controversy over whether
DC and macrophages can be separated based on either
their functions or transcriptomes [13, 104]. Most of the
studies in experimental mice have defined conventional DC
based on their expression of a limited number of cell surface
markers such as the integrin CD11c (integrin alpha x (Itgax)).
Murine conventional DC do express CD11c highly, but
this integrin is not restricted to these cells as most MNP
express CD11c, including the majority of the MNP within
the intestine [12]. Large numbers of DC-like cells can be
prepared in vitro following the treatment of bone marrow
cells ormonocytes withGM-CSF and IL-4.The cells obtained
from these preparations do sharemany typical characteristics
of conventionalDC, such as expression of high levels ofCD11c
and potent antigen-presenting activity, but macrophages can
also share these characteristics [13, 104]. Furthermore, at
the transcriptomic level these in vitro bone marrow-derived
or monocyte-derived DC prepared from mice and humans
are indistinguishable from macrophages and do not cluster
with conventional DC enriched from tissues [11, 13, 105]
(Figure 5).While data clearly show thatMNPmay havemany
important effects during prion infection, further studies are
necessary to distinguish between the separate roles of DC and
macrophages in disease pathogenesis in experimental rodents
and natural host species.
11.3. DC-Based Antiprion Immunotherapy. As well as playing
an important role in the establishment of a peripherally
acquired prion infection, current data suggest that con-
ventional DC may potentially be manipulated in order to
provide immunotherapeutic protection against peripherally
acquired prion diseases. As proof-of-principal studies have
shown, a conventional DC-based immunotherapy approach
can overcome host tolerance towards PrPC and impede
peripheral prion disease pathogenesis [54, 106, 107]. Finally,
the early accumulation of prions in the draining lymphoid
tissue is impeded and disease susceptibility reduced in the
absence of CD11c+ cells at the time of exposure [22–24, 39].
Therefore, the identification of the molecular factors which
influence the handling of prions by CD11c+ MNP may reveal
novel targets for therapeutic intervention in the initial phase
of infection with these invariably fatal neurodegenerative
diseases.
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